$89.00
USD
Research Use Only (RUO) • Not for Human or Veterinary Use • Not for Consumption.
Retatrutide (also searched as retatrutide peptide, RETA peptide, or is an investigational retatrutide research peptide studied as a triple receptor agonist targeting GIP, GLP-1, and Glucagon (GCG) receptors. In research contexts, this multi-receptor profile supports controlled studies of complex metabolic signaling interactions in laboratory models.
Common searches include retatrutide 10mg, retatrutide 20mg, and retatrutide 30mg (research context). Choose the strength that matches your protocol and documentation requirements.
Shipping Destination: USA only.
A frequent query is “what is retatrutide”. Retatrutide is a synthetic peptide developed for research on receptor signaling involving GIP, GLP-1, and glucagon pathways. For a deeper overview (research context), see: Retatrutide Peptide: Structure, Classification & Research Overview.
In controlled research settings, retatrutide mechanism of action refers to its studied activity as a triple receptor agonist that activates GLP-1, GIP, and GCG receptors. For a related classification guide, see: Is Retatrutide a Steroid? Structural Classification & Mechanism of Action.
Retatrutide vs tirzepatide is a common comparison. In research terms, retatrutide is studied as a triple agonist (GIP / GLP-1 / GCG), while tirzepatide is commonly referenced as a dual agonist (GIP / GLP-1). Read the full comparison here: Retatrutide vs Tirzepatide — Key Research Differences.
| Product Name | Retatrutide (Research Grade) |
|---|---|
| Label / Common | RETA / LY3437943 |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C221H342N46O68 |
| Molecular Weight | ~4731 g/mol |
| Target Receptors | GIP / GLP-1 / Glucagon (GCG) |
| Purity | ≥99% (HPLC verified; per lot CoA) |
| Form | Lyophilized White Powder |
| Endotoxin Level | < 1.0 EU/mg (where stated on lot documentation) |
Each batch includes a Certificate of Analysis (CoA) with lot/batch traceability. Purity is verified by HPLC and reported on the CoA to support reproducibility in research workflows. For sourcing guidance in a research context, see: Where to Buy Retatrutide for Research Purposes.
Retatrutide peptide is an investigational synthetic peptide studied for multi-receptor signaling in controlled research models. It is also referenced as RETA peptide or LY3437943.
LY3437943 is a commonly used identifier for retatrutide in research and scientific literature.
No. Retatrutide is not FDA approved and is supplied strictly as a research-use-only (RUO) compound.
Retatrutide is a synthetic peptide and not a steroid.
In research contexts, retatrutide is studied as a triple agonist targeting GIP, GLP-1, and GCG (glucagon) receptors.
Retatrutide is studied as a triple agonist (GIP / GLP-1 / GCG), while tirzepatide is commonly referenced as a dual agonist (GIP / GLP-1) in research literature.
Purity is verified by HPLC and documented on the lot-specific CoA.
